Company Overview - UnitedHealth Group closed at $282.69, down 19.61% after Q4 results showed significant operational earnings decline and restructuring charges [1] - The stock's trading volume reached 65.3 million shares, over 640% above its three-month average of 7.5 million shares [1] - UnitedHealth Group has grown 195,498% since its IPO in 1984 [1] Market Movement - The S&P 500 added 0.41% to finish at 6,978.60, while the Nasdaq Composite gained 0.91% to close at 23,817.10 [2] - In the managed health care sector, Elevance Health closed at $322.92, down 14.33%, and The Cigna Group finished at $270.09, down 3.68% [2] Earnings and Outlook - UnitedHealth's Q4 earnings revealed disappointing revenues and a cautious outlook for 2026, with projected revenue of $439.0 billion, down from $447.6 billion for 2025 [3] - The company is cutting back operations, particularly in its Optum services division, which will further reduce revenues [3] - Medicare pressures are expected to continue impacting the entire sector as investors adjust their expectations [3]

Core Viewpoint - The stock prices of U.S. Medicare insurance companies have declined in pre-market trading following a proposal to slightly increase payment rates to these companies [1] Company Performance - Humana's stock dropped by 17% [1] - Elevance Health's stock fell by 8% [1] - Centene's stock decreased by 7.7% [1] - Molina Healthcare's stock declined by 7.3% [1]

Core Viewpoint - Shares of major health insurance companies experienced significant declines in premarket trading following a proposal from the Trump administration to maintain flat Medicare payment rates in 2027, which did not meet Wall Street expectations [1][3]. Group 1: Stock Performance - UnitedHealth Group's shares fell nearly 9% to $317.51 [2] - CVS Health's stock price dropped 9.38% to $76 [2] - Centene's stock price decreased to $44.26, down 4.36% from the previous close [2] - Elevance Health's shares declined nearly 7% to $350.93 [2] - Humana's shares were the most affected, falling to $229, down more than 13.1% from Monday's closing [2] Group 2: Medicare Payment Rate Proposal - The Centers for Medicare & Medicaid Services proposed a 0.09% increase in Medicare Advantage payment rates for 2027, significantly lower than analysts' expectations of a 4-6% increase [3] - The previous year's increase was 5.06%, which exceeded forecasts [3] - The lower proposed increase follows President Trump's criticism of insurance companies, indicating a desire for them to earn less [3] Group 3: Official Statement - CMS Administrator Dr. Mehmet Oz stated that the proposed payment policies aim to ensure that Medicare Advantage functions better for the beneficiaries it serves [4]

Core Viewpoint - Elevance Health (ELV) is expected to report a quarterly earnings per share (EPS) of $3.07, reflecting a decline of 20.1% year-over-year, while revenues are forecasted to increase by 10.1% to $49.53 billion [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.2% lower in the last 30 days, indicating a reevaluation by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3]. Revenue Projections - Analysts predict 'Revenues- Service fees' at $2.13 billion, a year-over-year increase of 4.7% [5]. - 'Revenues- Premiums' are estimated at $40.69 billion, reflecting a 12.3% year-over-year increase [5]. - 'Revenues- Net investment income' is expected to reach $469.69 million, indicating a decline of 10.9% year-over-year [5]. - 'Revenues- Product revenue' is projected at $6.82 billion, a 1.5% year-over-year increase [6]. Membership Metrics - Total Medical Membership is projected to be 45.40 million, down from 45.73 million in the same quarter last year [6]. - 'Medical Membership - Medicare - Medicare Advantage' is estimated at 2.24 million, up from 2.07 million year-over-year [7]. - 'Medical Membership - Medicaid' is expected to be 8.60 million, down from 8.92 million year-over-year [7]. - 'Medical Membership - Federal Employees Health Benefits' is projected at 1.63 million, slightly down from 1.66 million year-over-year [8]. - Total Medicare membership is expected to reach 3.11 million, up from 2.96 million year-over-year [8]. - 'Medical Membership - Commercial Risk-Based - Individual' is estimated at 1.33 million, up from 1.29 million year-over-year [9]. - 'Benefit Expense Ratio' is forecasted to be 93.4%, compared to 92.4% year-over-year [9]. - 'Medical Membership - Commercial Fee-Based' is expected to be 27.08 million, down from 27.20 million year-over-year [9]. Stock Performance - Elevance Health shares have returned +8.4% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change [10]. - The company holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market [10].

Core Viewpoint - Elevance Health, Inc. (ELV) is expected to report its fourth-quarter 2025 results on January 28, 2026, with earnings estimated at $3.10 per share and revenues of $49.59 billion [1] Financial Performance - The fourth-quarter earnings estimate has seen one downward revision and no upward revisions in the past month, indicating a year-over-year decline of 19.3% in earnings, while revenues are projected to increase by 10.2% year-over-year [2] - For the full year 2025, the Zacks Consensus Estimate for Elevance's revenues is $197.98 billion, reflecting a 13% year-over-year increase, while the EPS estimate is $29.99, showing a 9.2% year-over-year decrease [3] Earnings Prediction - The current Earnings ESP for Elevance is -1.41%, and it holds a Zacks Rank of 4 (Sell), suggesting that an earnings beat is unlikely this quarter [4] Revenue Drivers - The consensus estimate for product revenues indicates a 1.5% growth from the previous year's $6.7 billion, while premiums are expected to rise by 12.3% year-over-year, contributing to overall sales growth [5] - The estimate for Commercial Individual membership suggests a 3.5% growth year-over-year, although Commercial Fee-based memberships are projected to decline by 0.4% [6] Operating Income - The Zacks Consensus Estimate for Carelon brand's operating income indicates an 8.9% year-over-year increase, driven primarily by growth in CarelonRx, while the Health Benefits segment's operating income is expected to rise by 12.1% [7] Expense Outlook - Elevated expenses are anticipated due to significant investments in digital capabilities, with total expenses expected to increase by 8.4% year-over-year in the fourth quarter [8]

Group 1 - The company Elevra Lithium Limited will release its December 2025 Quarterly Activities Report on January 28, 2026 AEDT [1] - An investor webcast will be held on the same day at 10.30am AEDT to discuss the quarterly results [1] - Retail shareholders and investors can participate in the webcast and submit written questions [2] Group 2 - Elevra has changed its presentation currency from Australian dollars to United States dollars effective July 1, 2025 [4] - This change aims to align with the predominant currency of revenue generation, providing clearer performance insights by reducing foreign exchange volatility [5] - The December 2025 Quarterly Report and FY26 Half-Year financial results will be presented in USD, with historical information also included for comparison [6]

Core Viewpoint - Artisan Value Fund's third-quarter 2025 investor letter indicates a continued equity market rally driven by strong corporate earnings, rising AI investment, and favorable US fiscal policies, despite concerns over tariffs [1] Group 1: Fund Performance - The Artisan Value Fund's Investor Class ARTLX, Advisor Class APDLX, and Institutional Class APHLX returned 0.83%, 0.91%, and 0.90% respectively in Q3 2025, underperforming the Russell 1000 Value Index which returned 5.33% [1] Group 2: Accenture plc (NYSE:ACN) Overview - Accenture plc reported a one-month return of 5.31% but has seen a 52-week decline of 23.09%, with shares closing at $271.09 and a market capitalization of $166.8 billion as of December 26, 2025 [2] - The company is recognized for its management consulting, technology, and outsourcing services, and is considered a potential "AI loser" due to fears of disruption from AI technologies [3] Group 3: Investment Insights - Artisan Value Fund made new purchases in Q3 2025, including Accenture, Salesforce, and Elevance Health, emphasizing that fears of AI disruption for established companies like Accenture may be exaggerated [3] - Accenture's growth has slowed in 2025, attributed to broader macroeconomic conditions rather than AI disruption, and the company meets the fund's margin of safety criteria due to strong free cash flow and solid balance sheets [3] - Despite being held by 66 hedge fund portfolios at the end of Q3, Accenture is not among the top 30 most popular stocks among hedge funds, indicating a potential undervaluation [4]

Group 1: Market Overview - The equity market rally continued in Q3 2025, driven by strong corporate earnings, rising AI investment, and expectations of economic support from US fiscal policy and lower interest rates [1] - Artisan Value Fund's Investor Class ARTLX, Advisor Class APDLX, and Institutional Class APHLX returned 0.83%, 0.91%, and 0.90% respectively, underperforming the Russell 1000 Value Index which returned 5.33% [1] Group 2: Salesforce, Inc. (NYSE:CRM) Performance - Salesforce, Inc. reported a one-month return of 14.28% but experienced a 20.75% decline in share value over the last 52 weeks, closing at $266.08 per share with a market capitalization of $253.308 billion on December 26, 2025 [2] - In Q3 2025, Salesforce was highlighted as a new purchase by Artisan Value Fund, alongside Accenture and Elevance Health, despite concerns about being disrupted by AI [3] Group 3: Investment Insights - Artisan Value Fund believes fears regarding AI disrupting established companies like Salesforce are overblown, attributing growth slowdowns to broader macroeconomic conditions rather than AI [3] - Salesforce's revenue for Q3 2026 was reported at $10.26 billion, reflecting a 9% year-over-year increase and an 8% increase in constant currency [4]

Group 1 - Elevance Health will release its fourth quarter and full year 2025 financial results on January 28, 2026, at 6:00 a.m. EST [1] - A conference call to review these results and the company's outlook will take place at 8:30 a.m. EST on the same day [1] - The conference call can be accessed via specific domestic and international numbers, with a replay available from January 28, 2026, until February 27, 2026 [3] Group 2 - Elevance Health serves 109 million consumers through a diverse portfolio of healthcare solutions, including medical, pharmacy, behavioral, clinical, home health, and complex care [2] - The company's purpose is to improve the health of humanity by supporting consumers, families, and communities throughout their healthcare journey [2]

Group 1: Drug Price Cuts and Pharmaceutical Stocks - President Trump announced significant drug price cuts in collaboration with nine major pharmaceutical companies, aiming to align U.S. drug costs with those in other developed nations [2] - Despite the announcement of price cuts, shares of involved drugmakers like GSK, Merck, Amgen, Novartis, Sanofi, and Roche rose by approximately 1% to 3%, as the deals removed the immediate threat of punitive tariffs for three years [3] - Analysts noted that the deals serve more as a public relations strategy rather than a substantial change in company economics, with Medicaid already benefiting from significant discounts [4] Group 2: Market Reactions to Health Insurers - Major health insurers such as Cigna, CVS Health, Elevance Health, and UnitedHealth Group experienced an initial dip of about 1% following Trump's comments but quickly recovered, indicating a market accustomed to Trump's policy announcements [5] Group 3: Merger of Trump Media & Technology Group and TAE Technologies - Trump Media & Technology Group announced a merger with TAE Technologies, valuing the combined entity at $6 billion, which led to a 42% surge in DJT shares, closing at $14.86 [7] - The merger has drawn mixed reactions, with some analysts viewing it as a significant move towards creating a public nuclear fusion company, while others criticized it as a questionable venture [9] Group 4: Tariff Threats and Market Volatility - Throughout 2025, Trump's threats and impositions of tariffs, particularly against China, have caused significant market volatility, including a $5 trillion market wipeout following an April tariff announcement [11] - The S&P 500 and Nasdaq Composite experienced substantial declines during tariff threats, but the market has shown resilience, often recovering to new highs [12] Group 5: Overall Market Environment - As 2025 concludes, the financial markets continue to be influenced by Trump's unpredictable policies, creating a landscape where traditional analysis is often overshadowed by political developments [13]